A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.

Elife · 2022 · PMC8989416 · PMID 35314027

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

In addition, PeptiCRAd1 (PC1) showed a clear trend towards an improved antitumor growth control in the untreated tumor in contrast to all other groups ( Figure 7B , left panel).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.